MA51971B2 - STEROIDS AND THEIR PROTEIN CONJUGATES - Google Patents

STEROIDS AND THEIR PROTEIN CONJUGATES

Info

Publication number
MA51971B2
MA51971B2 MA51971A MA51971A MA51971B2 MA 51971 B2 MA51971 B2 MA 51971B2 MA 51971 A MA51971 A MA 51971A MA 51971 A MA51971 A MA 51971A MA 51971 B2 MA51971 B2 MA 51971B2
Authority
MA
Morocco
Prior art keywords
steroids
protein conjugates
protein
conjugates
glucocorticoids
Prior art date
Application number
MA51971A
Other languages
French (fr)
Other versions
MA51971A1 (en
Inventor
William Olson
Amy Han
J Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2017/060434 external-priority patent/WO2018089373A2/en
Publication of MA51971A1 publication Critical patent/MA51971A1/en
Publication of MA51971B2 publication Critical patent/MA51971B2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des conjugués de stéroïdes protéiques qui sont utiles, par exemple, pour l'administration spécifique à une cible de glucocorticoïdes (gc) à des cellules.The invention relates to protein steroid conjugates that are useful, for example, for target-specific delivery of glucocorticoids (gc) to cells.

MA51971A 2016-11-08 2017-11-07 STEROIDS AND THEIR PROTEIN CONJUGATES MA51971B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419365P 2016-11-08 2016-11-08
PCT/US2017/060434 WO2018089373A2 (en) 2016-11-08 2017-11-07 Steroids and protein-conjugates thereof

Publications (2)

Publication Number Publication Date
MA51971A1 MA51971A1 (en) 2022-06-30
MA51971B2 true MA51971B2 (en) 2024-05-31

Family

ID=72291376

Family Applications (4)

Application Number Title Priority Date Filing Date
MA51970A MA51970B1 (en) 2016-11-08 2017-11-07 STEROIDS AND THEIR PROTEIN CONJUGATES
MA51969A MA51969B2 (en) 2016-11-08 2017-11-07 STEROIDS AND THEIR PROTEIN CONJUGATES
MA45752A MA45752B2 (en) 2016-11-08 2017-11-07 Steroids and their protein conjugates
MA51971A MA51971B2 (en) 2016-11-08 2017-11-07 STEROIDS AND THEIR PROTEIN CONJUGATES

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MA51970A MA51970B1 (en) 2016-11-08 2017-11-07 STEROIDS AND THEIR PROTEIN CONJUGATES
MA51969A MA51969B2 (en) 2016-11-08 2017-11-07 STEROIDS AND THEIR PROTEIN CONJUGATES
MA45752A MA45752B2 (en) 2016-11-08 2017-11-07 Steroids and their protein conjugates

Country Status (2)

Country Link
CL (1) CL2023000971A1 (en)
MA (4) MA51970B1 (en)

Also Published As

Publication number Publication date
MA51969B2 (en) 2024-05-31
MA51970B1 (en) 2023-11-30
MA45752A1 (en) 2020-06-30
MA51969A1 (en) 2022-08-31
MA45752B2 (en) 2022-12-30
MA51970A1 (en) 2022-08-31
MA51971A1 (en) 2022-06-30
CL2023000971A1 (en) 2023-09-29

Similar Documents

Publication Publication Date Title
MA50259A1 (en) Steroids and their antibody conjugates
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MA49726B1 (en) ANTI-CGRP ANTIBODY FORMULATION
MA45029A (en) ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT
MX2023011657A (en) Compositions comprising curons and uses thereof.
JOP20200228A1 (en) Compositions and methods for decreasing tau expression
JOP20200157B1 (en) Heavy chain antibodies that bind to CD22
BR112021016056A2 (en) Claudin 6 antibodies and their uses
MA40513A (en) DRUG-ANTIBODY ANTI-CDH6 CONJUGATES
MA40132B1 (en) Macrocyclic Inhibitors of Protein / protein Interactions pd-1 / pd-11 and cd80 (b7-1) / pd-li
MA41013B1 (en) Compositions comprising bacterial strains
BR112018016450A2 (en) vcn enhancer compositions and methods of using them
MA46619B1 (en) Anti-il-33 antibodies and their uses
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MA43773B1 (en) Engineered immunoglobulins with altered FcRn binding
MX2021006945A (en) Anellosomes for delivering protein replacement therapeutic modalities.
BR112018009004A8 (en) anti-cd3-folate conjugates and their uses
MX2021003797A (en) Immunoablative therapies.
MX2020003219A (en) Antibodies having specificity for btn2 and uses thereof.
MX2021006941A (en) Anellosomes for delivering intracellular therapeutic modalities.
MY191894A (en) Antibodies that bind zika virus envelope protein and uses thereof
MX390865B (en) Compositions and methods for the treatment of complications and disorders relating to von willebrand factor
MX2020013389A (en) Terlipressin compositions and uses thereof.
MA51969B2 (en) STEROIDS AND THEIR PROTEIN CONJUGATES
EA201900275A1 (en) STEROIDS AND THEIR PROTEIN CONJUGATES